Type:Injection
Generic Name:Suxamethonium Chloride (Succinylcholine)
Manufacturer:Chemist Laboratories Ltd.
Price:৳0.00
Muscle relaxant
Reconstitution: IV infusion: Suxamethonium Cl 1 g powd for inj or 20 mL of a soln containing 50 mg/mL may be added to 1,000 mL or 500 mL of diluent (e.g. dextrose 5%, dextrose 5% and NaCl 0.9%, NaCl 0.9%, or (1/6) M Na lactate inj) to provide a soln containing 1 mg/mL (0.1%) or 2 mg/mL (0.2%), respectively. Alternatively, suxamethonium Cl 500 mg powd for inj or 10 mL of a soln containing 50 mg/mL may be added to 500 mL or 250 mL of diluents to provide a soln containing 1 mg/mL (0.1%) or 2 mg/mL (0.2%), respectively.
Intravenous Muscle relaxant in general anaesthesia Adult: As suxamethonium Cl: Single dose of 0.3-1.1 mg/kg by inj. Supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. For prolonged procedures, 0.1-0.2% soln by infusion at 2.5-4 mg/min, adjusted as necessary. Max (repeated inj or continuous infusion): 500 mg/hr. Intramuscular Muscle relaxant in general anaesthesia Adult: As suxamethonium Cl: 3-4 mg/kg. Max: 150 mg.
Intravenous Muscle relaxant in general anaesthesia Child: As suxamethonium Cl: <1 yr 2 mg/kg; 1-12 yr 1 mg/kg. Intramuscular Muscle relaxant in general anaesthesia Child: As suxamethonium Cl: <1 yr Up to 5 mg/kg; >1 yr Up to 4 mg/kg. Max: 150 mg.
Genetic disorders of plasma pseudocholinesterase, personal/family history of malignant hyperthermia, hypersensitivity from previous neuromuscular drug, severe burns, massive trauma, extensive denervation of skeletal muscle, patients with risk of hyperkalaemia, renal impairment, angle closure glaucoma.
Suxamethonium chloride is an ultrashort-acting depolarising type skeletal muscle relaxant. It blocks the neuromuscular junction by binding to the cholinergic receptors and depolarising it.
Hypersensitivity to any neuromuscular blocker. Patient w/ reduced plasma cholinesterase activity, bone fractures, neuromuscular disorders, cardiac or resp disease, electrolyte imbalance, suspected cardiac glycoside toxicity. Childn. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function and oxygenation during admin; temp, serum K and Ca, assisted ventilator status; neuromuscular function w/ peripheral nerve stimulator.
Prolonged resp depression or apnoea, bradycardia, tachycardia, hypotension, HTN, raised intraocular pressure, hyperkalaemia, muscle fasciculation, excessive salivation, jaw rigidity, rash. Potentially Fatal: Anaphylactic and anaphylactoid reactions, acute rhabdomyolysis w/ hyperkalaemia followed by ventricular dysrhythmias and cardiac arrest, malignant hyperthermia.
Prolonged neuromuscular blocking effects w/ specific anticholinesterase agents (e.g. neostigmine), cytotoxic compd (e.g. cyclophosphamide), antiarrhythmics (e.g. quinidine), aminoglycosides, psychiatric drugs (e.g. chlorpromazine), Mg salts, anaesth agents (e.g. morphine), SSRIs, organophosphate insecticides. Increased susceptibility to the effects of suxamethonium-exacerbated hyperkalaemia w/ digitalis-like drugs.
Suxalax IM/IVPrice: ৳17.00
Square Pharmaceuticals PLC.
NeosuxaPrice: ৳8.42
Popular Pharmaceuticals Ltd.